Light-Emitting Diode Photobiomodulation After Cerebra Ischemia
Light-Emitting Diode Photobiomodulation After Cerebra Ischemia
复制标题
DOI：
10.3389/fneur.2019.00911
复制
发表时间：
2019-08-22
影响因子：
3.4
通讯作者：
Iglesias-Rey, Ramon
中科院分区：
文献类型：
--
作者：
Argibay, Barbara;Campos, Francisco;Iglesias-Rey, Ramon
光生物调节(PBM)疗法是一种很有前途的治疗方法，可用于包括中风在内的多种病理疾病。PBM治疗脑缺血的生物学效应之前已经被作为一种神经保护策略来探索，使用不同的光源、波长和入射光功率。然而，PBM作为一种新的替代疗法来刺激缺血性卒中后受损神经元组织的恢复的能力尚未得到很好的探索。本研究的目的是探讨利用发光二极管(LED)进行低强度光照射治疗中风的潜在策略。首先在不同能量密度下对C17.2永生化小鼠神经前体细胞系进行了LED光生物调制(波长830 nm，0.2-0.6J/cm(2))，以观察该处理对细胞的增殖和活力是否有影响。然后，在脑缺血动物模型上，通过病变缩小、行为缺陷和功能磁共振成像(FMRI)分析PBM-LED(连续波，830 nm，大脑皮质0.28J/cm(2))对长期恢复(12周)的影响。PBM后的细胞增殖分析在所有不同的暴露时间都显著增加(1 MW)；然而，这种影响不能在体内实验条件下复制，因为PBM没有显示出梗塞减少或功能恢复。尽管PBM的治疗效果很有希望，但在与神经康复相关的机制方面，有必要进行进一步的临床前研究，以优化这种新疗法的治疗窗口，并降低未来临床试验中失败的风险。
Photobiomodulation (PBM) therapy is a promising therapeutic approach for several pathologies, including stroke. The biological effects of PBM for the treatment of cerebral ischemia have previously been explored as a neuroprotective strategy using different light sources, wavelengths, and incident light powers. However, the capability of PBM as a novel alternative therapy to stimulate the recovery of the injured neuronal tissue after ischemic stroke has been poorly explored. The aim of this study was to investigate the low-level light irradiation therapy by using Light Emitting Diodes (LEDs) as potential therapeutic strategy for stroke. The LED photobiomodulation (continuous wave, 830 nm, 0.2-0.6 J/cm(2)) was firstly evaluated at different energy densities in C17.2 immortalized mouse neural progenitor cell lines, in order to observe if this treatment had any effect on cells, in terms of proliferation and viability. Then, the PBM-LED effect (continuous wave, 830 nm, 0.28 J/cm(2) at brain cortex) on long-term recovery (12 weeks) was analyzed in ischemic animal model by means lesion reduction, behavioral deficits, and functional magnetic resonance imaging (fMRI). Analysis of cellular proliferation after PBM was significantly increased (1 mW) in all different exposure times used; however, this effect could not be replicated in vivo experimental conditions, as PBM did not show an infarct reduction or functional recovery. Despite the promising therapeutic effect described for PBM, further preclinical studies are necessary to optimize the therapeutic window of this novel therapy, in terms of the mechanism associated to neurorecovery and to reduce the risk of failure in futures clinical trials.